Prostate cancer trends in Asia

Hideyuki Akaza, Mizuki Onozawa, Shiro Hinotsu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Differences in the incidence and mortality rates for prostate cancer between East and West are clearly defined, with higher rates in the West and lower rates in the East. Treatment methods are generally selected in accordance with general practice guidelines, but the current reality in Asia is that there is not sufficient clinical data to set Asia-specific guidelines for treatment. This leads to a situation whereby for the large part guidelines based on scientific evidence accumulated in Western countries are followed, but from time to time cases are encountered when such guidelines may not be considered to be the most appropriate for the case at hand. Methods and Results: Although there is a relatively large volume of clinical evidence relating to endocrine therapy in Asia, the treatment choices and effects differ to those in the West. These regional differences are thought to be due to various factors, including not only differences in genetic background, but also distinct differences in the living and healthcare environments. If the differences between East and West in terms of trends in prostate cancer could be examined, with positive aspects being adopted and negative aspects being improved, this could also be expected to be of use in developing a better treatment strategy for prostate cancer. The exchanging of information on a broader, global level will enable improvements in prevention, diagnosis and treatment of prostate cancer. Conclusion: It is in pursuit of this objective that it is important to promote high-quality clinical trials and joint epidemiological studies in Asia and work to accumulate data that are comparable to data available in Western countries.

Original languageEnglish
Pages (from-to)859-865
Number of pages7
JournalWorld Journal of Urology
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Prostatic Neoplasms
Guidelines
Practice Guidelines
General Practice
Epidemiologic Studies
Hand
Clinical Trials
Delivery of Health Care
Mortality
Incidence
Therapeutics

Keywords

  • Asia
  • Epidemiology
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Akaza, H., Onozawa, M., & Hinotsu, S. (2017). Prostate cancer trends in Asia. World Journal of Urology, 35(6), 859-865. https://doi.org/10.1007/s00345-016-1939-7

Prostate cancer trends in Asia. / Akaza, Hideyuki; Onozawa, Mizuki; Hinotsu, Shiro.

In: World Journal of Urology, Vol. 35, No. 6, 01.06.2017, p. 859-865.

Research output: Contribution to journalArticle

Akaza, H, Onozawa, M & Hinotsu, S 2017, 'Prostate cancer trends in Asia', World Journal of Urology, vol. 35, no. 6, pp. 859-865. https://doi.org/10.1007/s00345-016-1939-7
Akaza, Hideyuki ; Onozawa, Mizuki ; Hinotsu, Shiro. / Prostate cancer trends in Asia. In: World Journal of Urology. 2017 ; Vol. 35, No. 6. pp. 859-865.
@article{10861a16acd44e24b1ea017522d27fc8,
title = "Prostate cancer trends in Asia",
abstract = "Introduction: Differences in the incidence and mortality rates for prostate cancer between East and West are clearly defined, with higher rates in the West and lower rates in the East. Treatment methods are generally selected in accordance with general practice guidelines, but the current reality in Asia is that there is not sufficient clinical data to set Asia-specific guidelines for treatment. This leads to a situation whereby for the large part guidelines based on scientific evidence accumulated in Western countries are followed, but from time to time cases are encountered when such guidelines may not be considered to be the most appropriate for the case at hand. Methods and Results: Although there is a relatively large volume of clinical evidence relating to endocrine therapy in Asia, the treatment choices and effects differ to those in the West. These regional differences are thought to be due to various factors, including not only differences in genetic background, but also distinct differences in the living and healthcare environments. If the differences between East and West in terms of trends in prostate cancer could be examined, with positive aspects being adopted and negative aspects being improved, this could also be expected to be of use in developing a better treatment strategy for prostate cancer. The exchanging of information on a broader, global level will enable improvements in prevention, diagnosis and treatment of prostate cancer. Conclusion: It is in pursuit of this objective that it is important to promote high-quality clinical trials and joint epidemiological studies in Asia and work to accumulate data that are comparable to data available in Western countries.",
keywords = "Asia, Epidemiology, Prostate cancer",
author = "Hideyuki Akaza and Mizuki Onozawa and Shiro Hinotsu",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s00345-016-1939-7",
language = "English",
volume = "35",
pages = "859--865",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Prostate cancer trends in Asia

AU - Akaza, Hideyuki

AU - Onozawa, Mizuki

AU - Hinotsu, Shiro

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Introduction: Differences in the incidence and mortality rates for prostate cancer between East and West are clearly defined, with higher rates in the West and lower rates in the East. Treatment methods are generally selected in accordance with general practice guidelines, but the current reality in Asia is that there is not sufficient clinical data to set Asia-specific guidelines for treatment. This leads to a situation whereby for the large part guidelines based on scientific evidence accumulated in Western countries are followed, but from time to time cases are encountered when such guidelines may not be considered to be the most appropriate for the case at hand. Methods and Results: Although there is a relatively large volume of clinical evidence relating to endocrine therapy in Asia, the treatment choices and effects differ to those in the West. These regional differences are thought to be due to various factors, including not only differences in genetic background, but also distinct differences in the living and healthcare environments. If the differences between East and West in terms of trends in prostate cancer could be examined, with positive aspects being adopted and negative aspects being improved, this could also be expected to be of use in developing a better treatment strategy for prostate cancer. The exchanging of information on a broader, global level will enable improvements in prevention, diagnosis and treatment of prostate cancer. Conclusion: It is in pursuit of this objective that it is important to promote high-quality clinical trials and joint epidemiological studies in Asia and work to accumulate data that are comparable to data available in Western countries.

AB - Introduction: Differences in the incidence and mortality rates for prostate cancer between East and West are clearly defined, with higher rates in the West and lower rates in the East. Treatment methods are generally selected in accordance with general practice guidelines, but the current reality in Asia is that there is not sufficient clinical data to set Asia-specific guidelines for treatment. This leads to a situation whereby for the large part guidelines based on scientific evidence accumulated in Western countries are followed, but from time to time cases are encountered when such guidelines may not be considered to be the most appropriate for the case at hand. Methods and Results: Although there is a relatively large volume of clinical evidence relating to endocrine therapy in Asia, the treatment choices and effects differ to those in the West. These regional differences are thought to be due to various factors, including not only differences in genetic background, but also distinct differences in the living and healthcare environments. If the differences between East and West in terms of trends in prostate cancer could be examined, with positive aspects being adopted and negative aspects being improved, this could also be expected to be of use in developing a better treatment strategy for prostate cancer. The exchanging of information on a broader, global level will enable improvements in prevention, diagnosis and treatment of prostate cancer. Conclusion: It is in pursuit of this objective that it is important to promote high-quality clinical trials and joint epidemiological studies in Asia and work to accumulate data that are comparable to data available in Western countries.

KW - Asia

KW - Epidemiology

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84988373701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988373701&partnerID=8YFLogxK

U2 - 10.1007/s00345-016-1939-7

DO - 10.1007/s00345-016-1939-7

M3 - Article

C2 - 27644231

AN - SCOPUS:84988373701

VL - 35

SP - 859

EP - 865

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 6

ER -